Document Detail


Understanding the Critical Disposition Pathways of Statins to Assess Drug-Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1.
MedLine Citation:
PMID:  23047648     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The use of statins is widespread across disease areas because many patients have comorbidities. Given that these drugs have become common as comedications, it is essential to have an understanding of the potential risks of drug-drug interactions (DDIs) between statins and candidate drugs in development. Although the hepatic uptake transporter organic anion-transporting polypeptide 1B1 (OATP1B1) is known to play a substantial role in statin-related DDI risk, other transporters and metabolizing enzymes can also be involved. Consequently, a holistic approach to risk assessment is required, tailored to each statin. Using evidence from pharmacogenetics, DDIs, and literature on absorption, distribution, metabolism, and elimination (ADME) in humans, this review identifies pathways that contribute the most to, and are therefore the most critical to, the disposition of each statin. It also provides an understanding of the expected theoretical maximum increase in systemic exposure if the disposition of a statin is inhibited. Finally, on a statin-by-statin basis, we propose in vitro inhibition studies that should be routinely conducted during drug development so as to better assess DDI risk.Clinical Pharmacology & Therapeutics (2012); advance online publication 10 October 2012. doi:10.1038/clpt.2012.163.
Authors:
R Elsby; C Hilgendorf; K Fenner
Related Documents :
24084158 - Antimalarial activity of compounds comprising a primary benzene sulfonamide fragment.
15608478 - Preliminary study on the efficacy and tolerability of newer anticonvulsants in a popula...
12848098 - When and how to stop antiepileptic drugs in adults.
24387348 - Drug interactions with phytotherapeutics in oncology.
7429608 - Antiinflammatory effects of free radical scavengers and antioxidants: further support f...
16384758 - Treatment of recalcitrant atopic dermatitis with omalizumab.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-10
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  -     ISSN:  1532-6535     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Global DMPK-In Vitro/In Silico ADME, AstraZeneca R&D Alderley Park, Cheshire, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combat-Related PTSD Nightmares and Imagery Rehearsal: Nightmare Characteristics and Relation to Trea...
Next Document:  Prenatal and Perinatal Environmental Influences on the Human Fetal and Placental Epigenome.